Amebiasis
Drug research and approvals for amebiasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 1 studies of amebiasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 1
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting Now
Newest start dates first, of 1 recruiting on ClinicalTrials.gov ↗- Parasitic Ulcer Treatment TrialNCT06213649 · Phase 3 · Jeremy Keenan, MD, MPH · starts Jul 1, 2024
Drug Pipeline
14 approved, 16 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Nitazoxanide, Metronidazole, Tinidazole, Quinacrine, Tilbroquinol, Emetine, Broxyquinoline, Clioquinol, Atovaquone, Paromomycin, Chlorquinaldol, Secnidazole, Ornidazole, Nimorazole
- Trimetrexate
- Phase 2 Dihydrofolate reductase inhibitor
- Diloxanide
- Phase 2
- Dehydroemetine
- Phase 2
- Azanidazole
- Phase 2
- Arsthinol
- Phase 2
- Glycobiarsol
- Phase 2
- Propenidazole
- Phase 2
- Teclozan
- Phase 2
- Phanquone
- Phase 2
- Etofamide
- Phase 2
- Difetarsone
- Phase 2
- Clefamide
- Phase 2
- Tenonitrozole
- Phase 2
- Fumagillin
- Phase 2
- Satranidazole
- Phase 2
- Auranofin
- Phase 1 Unknown
FDA Orphan Designations
Approved first, then open designations, newest first| May 17, 2004 | TindamaxTreatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three… | Presutti Laboratories, Inc. | Approved |
| Jun 19, 2017 | MiltefosineTreatment of disseminated amebiasis | Profounda, Inc. | Designated |
| Apr 30, 2010 | AuranofinTreatment of amebiasis | Ctr for Discovery & Innovation in Parasitic Diseas | Designated |
| Oct 23, 2001 | NitazoxanideTreatment for intestinal amebiasis | Romark Laboratories, L.C. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA